- Home
- GRNT vs AUPH Comparison
GRNT vs AUPH Comparison
Compare GRNT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- AUPH
- Stock Information
- Founded
- GRNT 2013
- AUPH 1993
- Country
- GRNT United States
- AUPH Canada
- Employees
- GRNT N/A
- AUPH N/A
- Industry
- GRNT Blank Checks
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- GRNT Finance
- AUPH Health Care
- Exchange
- GRNT Nasdaq
- AUPH Nasdaq
- Market Cap
- GRNT 856.4M
- AUPH 1.3B
- IPO Year
- GRNT N/A
- AUPH 1999
- Fundamental
- Price
- GRNT $6.85
- AUPH $7.55
- Analyst Decision
- GRNT Buy
- AUPH Strong Buy
- Analyst Count
- GRNT 3
- AUPH 3
- Target Price
- GRNT $7.60
- AUPH $10.33
- AVG Volume (30 Days)
- GRNT 795.0K
- AUPH 1.4M
- Earning Date
- GRNT 03-06-2025
- AUPH 02-13-2025
- Dividend Yield
- GRNT 6.42%
- AUPH N/A
- EPS Growth
- GRNT N/A
- AUPH N/A
- EPS
- GRNT 0.36
- AUPH N/A
- Revenue
- GRNT $358,521,000.00
- AUPH $220,361,000.00
- Revenue This Year
- GRNT $4.66
- AUPH $36.97
- Revenue Next Year
- GRNT $22.97
- AUPH $16.43
- P/E Ratio
- GRNT $19.01
- AUPH N/A
- Revenue Growth
- GRNT N/A
- AUPH 38.72
- 52 Week Low
- GRNT $5.20
- AUPH $4.71
- 52 Week High
- GRNT $7.10
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- GRNT 65.07
- AUPH 28.27
- Support Level
- GRNT $6.61
- AUPH $8.33
- Resistance Level
- GRNT $7.00
- AUPH $9.31
- Average True Range (ATR)
- GRNT 0.20
- AUPH 0.32
- MACD
- GRNT 0.08
- AUPH -0.19
- Stochastic Oscillator
- GRNT 87.90
- AUPH 1.68
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.